1. Home
  2. CAPR vs UAMY Comparison

CAPR vs UAMY Comparison

Compare CAPR & UAMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • UAMY
  • Stock Information
  • Founded
  • CAPR 2005
  • UAMY 1968
  • Country
  • CAPR United States
  • UAMY United States
  • Employees
  • CAPR N/A
  • UAMY N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • UAMY Metal Fabrications
  • Sector
  • CAPR Health Care
  • UAMY Industrials
  • Exchange
  • CAPR Nasdaq
  • UAMY Nasdaq
  • Market Cap
  • CAPR 324.6M
  • UAMY 316.8M
  • IPO Year
  • CAPR N/A
  • UAMY N/A
  • Fundamental
  • Price
  • CAPR $6.28
  • UAMY $4.54
  • Analyst Decision
  • CAPR Strong Buy
  • UAMY Strong Buy
  • Analyst Count
  • CAPR 8
  • UAMY 5
  • Target Price
  • CAPR $24.75
  • UAMY $3.60
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • UAMY 6.3M
  • Earning Date
  • CAPR 08-11-2025
  • UAMY 08-12-2025
  • Dividend Yield
  • CAPR N/A
  • UAMY N/A
  • EPS Growth
  • CAPR N/A
  • UAMY N/A
  • EPS
  • CAPR N/A
  • UAMY N/A
  • Revenue
  • CAPR $13,392,150.00
  • UAMY $25,728,046.00
  • Revenue This Year
  • CAPR N/A
  • UAMY $209.07
  • Revenue Next Year
  • CAPR $6,061.53
  • UAMY $98.95
  • P/E Ratio
  • CAPR N/A
  • UAMY N/A
  • Revenue Growth
  • CAPR N/A
  • UAMY 134.91
  • 52 Week Low
  • CAPR $3.98
  • UAMY $0.49
  • 52 Week High
  • CAPR $23.40
  • UAMY $5.13
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • UAMY 64.05
  • Support Level
  • CAPR $6.17
  • UAMY $4.38
  • Resistance Level
  • CAPR $7.30
  • UAMY $5.13
  • Average True Range (ATR)
  • CAPR 0.43
  • UAMY 0.40
  • MACD
  • CAPR -0.11
  • UAMY 0.01
  • Stochastic Oscillator
  • CAPR 4.53
  • UAMY 69.56

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

Share on Social Networks: